Burning Rock Biotech/BNR

$0.80

-5.47%
-
1D1W1MYTD1YMAX

About Burning Rock Biotech

Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.

Ticker

BNR

Sector

Healthcare

Trading on

NASDAQ

Industry

Healthcare Facilities

CEO

Yansheng Han

Employees

1,138

Headquarters

Guangzhou, China

BNR Metrics

BasicAdvanced
$87.17M
Market cap
-
P/E ratio
-$0.96
EPS
0.25
Beta
-
Dividend rate

What the Analysts think about BNR

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analysts.
395% upside
High $3.96
Low $3.96
$0.80
Current price
$3.96
Average price target

BNR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-137.17% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
¥127.5M
-12.79%
Net income
¥-174.9M
33.31%
Profit margin
-137.17%
52.85%

BNR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.11%
QuarterlyAnnual
Q4 21
Q1 22
Q2 22
Q3 22
Q4 22
Actual
-¥2.40
-¥2.50
-¥2.50
-¥2.23
-
Expected
-¥1.69
-¥2.41
-¥2.40
-¥2.35
-¥2.61
Surprise
42.01%
3.73%
4.17%
-5.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell Burning Rock Biotech stock

Buy or sell Burning Rock Biotech stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing